Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Phase 2

Conditions: Lymphoma
Fanconi Anemia
Myelodysplastic Syndromes
Sarcoma
Leukemia
Childhood Langerhans Cell Histiocytosis
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Radiation: radiation therapy
Drug: melphalan
Drug: fludarabine phosphate
Drug: methylprednisolone

First Posted Date: 2004-06-11

Last Posted Date: 2014-01-10

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 25

Registration Number: NCT00084695

Locations: 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Bone Marrow Transplantation in Treating Patients With Leukemia

Phase 3

Withdrawn

Conditions: Leukemia
Graft Versus Host Disease
Lymphoma

First Posted Date: 2004-06-09

Last Posted Date: 2020-01-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT00006451

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2004-06-08

Last Posted Date: 2012-12-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00005641

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes

First Posted Date: 2004-05-24

Last Posted Date: 2010-02-24

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 19

Registration Number: NCT00003187

Locations: 🇺🇸
University of South Carolina School of Medicine, Columbia, South Carolina, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

and more 10 locations

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Phase 3

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-05-21

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 750

Registration Number: NCT00002599

Locations: 🇬🇧
Leeds Teaching Hospital Trust, Leeds, England, United Kingdom

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myeloma

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: leucovorin calcium
Drug: methotrexate
Drug: methylprednisolone
Procedure: in vitro-treated bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2004-05-03

Last Posted Date: 2017-04-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00005988

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2004-04-28

Last Posted Date: 2014-05-02

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 36

Registration Number: NCT00003960

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Center for Cancer Treatment and Research, Columbia, South Carolina, United States